Enzyme Replacement Therapy Proves Safe and Stable in Chinese Patients with Fabry Disease
A 52-week phase 3 trial across six Chinese centers found agalsidase alfa was generally well tolerated, kept kidney and cardiac ...
A 52-week phase 3 trial across six Chinese centers found agalsidase alfa was generally well tolerated, kept kidney and cardiac ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine